# Kedalion Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kedalion-therapeutics

- Industry: Medical Devices & Equipment
- Headquarters: Menlo Park, US
- Website: www.kedalionthera.com
- Latest round: Series B (Nov 15, 2021)
- Investors on record: 2

## About

Kedalion Therapeutics, Inc. is a biotechnology company focused on advancing innovative treatments in ophthalmology, primarily through the development of novel delivery systems for eye medications.Founded in 2015 and headquartered in Menlo Park, US, Kedalion Therapeutics, Inc. specializes in ophthalmic therapies. The company was founded by Ehud Ivri and Mark Blumenkranz, both of whom have extensive backgrounds in the healthcare sector. In June 2022, Kedalion was acquired by Novartis Pharmaceuticals Corporation for an undisclosed sum. This acquisition is part of Novartis's strategy to enhance its portfolio in ophthalmology. The most recent funding, a Series A round in which they raised USD 5.00 mn, was led by Lagunita BioSciences, contributing to a total amount raised of USD 5.00 mn and a current company valuation of USD 13.502 mn.Kedalion Therapeutics, Inc. develops innovative medical solutions in ophthalmology, including its AcuStream™ technology. This electromechanical device facilitates precise dosing and accurate delivery of topical ophthalmic medications. This technology complements Novartis's existing offerings, such as Xiidra (lifitegrast ophthalmic solution) 5%, a treatment for dry eye disease, thereby addressing significant unmet medical needs in ocular health.Kedalion's revenue comes primarily through prescription sales of its innovative products, notably facilitated through partnerships with healthcare providers and pharmacies. The sales transactions occur within agreements that ensure direct access to patients in need of their ophthalmic treatments. The pricing for their products, such as Xiidra, is subject to regulation and negotiation within healthcare systems, ensuring compliance with reimbursement protocols set by insurers and government payors.Moving forward, Kedalion Therapeutics aims to expand its product offerings, focusing on the development of additional ophthalmic delivery systems. The recent acquisition by Novartis is expected to enhance their capabilities in addressing unmet patient needs in front-of-eye conditions. This strategic move aligns with Novartis's goal of growing its ophthalmics portfolio. The funding from the Series A round, completed on June 30, 2022, will be utilized to support these initiatives and further investigation into transformative ophthalmic methods.

## Funding rounds

- Series B, Nov 15, 2021 — Novartis Venture Fund, Lagunita BioSciences

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B
- Lagunita BioSciences — Series B